It helps manage blood sugar by triggering insulin release and reducing glucagon
Non-responders to tirzepatide may benefit from retatrutide's additional glucagon mechanism, but subgroup analyses of poor tirzepatide responders haven't been definitively published
The glucagon receptor activation begins contributing noticeably to energy expenditure, creating a metabolic environment where the body burns more calories at rest than it did before treatment
-1 ( [95% ] : -1,66 [-2,26 , -1,09 ]), , -
What factors could limit the widespread adoption of GLP-1 receptor agonists despite their proven benefits in HbA1c reduction, weight loss, and cardiovascular risk management, and how might healthcare systems address these barriers
Hypothesis: Replication of Phase 2 results (24 %) in a larger population over a longer duration